For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TSZ865. CME/MOC/NCPD/CE/AAPA/IPCE credit will be available until August 28, 2025.
Exchanging Ideas on How to Navigate Patient-Centric Clinical Decisions in Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TSZ865. CME/MOC/NCPD/CE/AAPA/IPCE credit will be available until August 28, 2025.
Exchanging Ideas on How to Navigate Patient-Centric Clinical Decisions in Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Disclosure information is available at the beginning of the video presentation.
129 Listeners
6 Listeners
31 Listeners
3 Listeners
3 Listeners
10 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
5 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
316 Listeners
42 Listeners
2 Listeners
114 Listeners
2 Listeners
483 Listeners
55 Listeners
43 Listeners
21 Listeners
321 Listeners
54 Listeners
9 Listeners
166 Listeners
38 Listeners